Top Markets
Coin of the day
Clarity Pharmaceuticals Ltd Clarity Pharmaceuticals Ltd

Clarity Pharmaceuticals Ltd

CU6
Rank in Stocks #11775
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company,... Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. The company was incorporated in 2010 and is based in Sydney, Australia.
Share Price
$1.77
Last synced: 2026-08-28
Market Cap
$660.45M
Change (1 day)
7.26%
Change (1 year)
-9.15%
Country
AU
Trade Clarity Pharmaceuticals Ltd (CU6)

Category

P/S ratio for Clarity Pharmaceuticals Ltd (CU6)
P/S ratio as of 2026 TTM: 0
According to Clarity Pharmaceuticals Ltd latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for Clarity Pharmaceuticals Ltd from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors